Charles River Laboratories
CRL NYSE· Life Sciences Tools & Services
Last close · Oct 26, 2026
$357.27
KIRA · Stoqly’s AI analyst, in plain words
- Charles River Laboratories had $4.0B of revenue in fiscal 2025, down 0.9% on the year before. Over five years, revenue changed +6.6% a year on average.
- Its operating margin was 0.6%, down 5.0 pts: of every 100 in sales, about 1 is left after running the business.
- Charles River Laboratories lost $144M in fiscal 2025.
- Free cash flow was $518M in fiscal 2025, 12.9% of revenue.
- Charles River Laboratories returned $361M to shareholders in fiscal 2025, 70% of free cash flow. The diluted share count fell 4.0%.
- Charles River Laboratories owes $1.9B more than it holds in cash, about 4.5 years of operating profit.
Market cap
$17.1B
P/E
—
Revenue
$4.0B
Net income
−$144M
Free cash flow
$518M
Operating margin
0.6%
Charles River Laboratories in 30 seconds · fiscal 2025
Are sales growing?
−0.9%
No. Sales fell 0.9% last year.
Does it make a profit?
−3.6%
No. It lost money last year.
Does profit turn into cash?
12.9%
Yes. 12.9% of sales ends up as free cash.
Is debt under control?
4.5x
Heavy. Repaying its debt would take 4.5 years of operating profit.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
What Charles River Laboratories does
No business description yet.
- Fiscal year ends
- December 27, 2025
- Latest annual report
- 10-K · Feb 18, 2026
- Legal name
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- CIK
- 0001100682
Charles River Laboratories · CRL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.5B | $4.0B | $4.1B | $4.1B | $4.0B |
| Revenue growth | 21.1% | 12.3% | 3.9% | −1.9% | −0.9% |
| Operating margin | 16.7% | 16.4% | 15.0% | 5.6% | 0.6% |
| Net income | $391M | $486M | $475M | $22.2M | −$144M |
| Net margin | 11.0% | 12.2% | 11.5% | 0.6% | −3.6% |
| Diluted EPS | $7.60 | $9.48 | $9.22 | $0.20 | −$2.91 |
| Cash | |||||
| Cash from operations | $761M | $620M | $684M | $735M | $738M |
| Capital expenditure | $229M | $325M | $319M | $233M | $219M |
| Free cash flow | $532M | $295M | $365M | $502M | $518M |
| FCF margin | 15.0% | 7.4% | 8.9% | 12.4% | 12.9% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $40.7M | $38.7M | $24.2M | $119M | $361M |
| Share count change | 1.6% | −0.2% | 0.3% | 0.3% | −4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $242M | $234M | $277M | $195M | $214M |
| Debt incl. finance leases | $2.7B | $2.7B | $2.7B | $2.2B | $2.1B |
| Shareholders' equity | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Net debt / EBITDA | 2.8x | 2.6x | 2.6x | 3.5x | 4.5x |
| Current ratio | 1.2x | 1.3x | 1.5x | 1.4x | 1.3x |
| Interest coverage | 8.0x | 11.0x | 4.5x | 1.8x | 0.2x |
| Returns and quality | |||||
| Return on capital | 11.1% | 9.9% | 8.9% | 2.0% | 0.4% |
| Return on equity | 16.8% | 17.7% | 14.4% | 0.6% | −4.4% |
| Piotroski F-score | 4 | 6 | 5 | 4 | 4 |
| Altman Z'' | 1.9 | 2.2 | 2.5 | 2.3 | 1.8 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$43.7M
6 insiders
Of sales under plans
93%
$40.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Charles River Laboratories · CRL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories CRL | $17.1B | −0.9% | 0.6% | 12.9% | 0.4% | — | 4 |
| Mettler Toledo MTD | $33.7B | 4.0% | — | 21.1% | 50.5% | 37.6x | 7 |
| Illumina ILMN | $41.5B | −0.7% | 18.6% | 21.4% | 20.3% | 50.6x | 8 |
| Waters WAT | $44.8B | 7.0% | 25.4% | 17.1% | 21.0% | — | 6 |
| Bio-Rad Laboratories BIO | $10.0B | 0.7% | 1.8% | 14.5% | 0.5% | 46.6x | 5 |
KIRA
At $357.27 a share, the company is worth $17.1B.
Charles River Laboratories grew sales faster than 0 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001100682). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.